Course Overview
Clinical management of the chronic cardiovascular disease is a key component of the work of advanced practice nurses and registered nurses in the cardiology and primary care settings. PCNA’s 2022 pharmacology CE course is designed to meet the clinical practice and recertification needs of these clinicians.
This 2022 curriculum includes a comprehensive approach to pharmacology in:
- Prevention and Treatment of COVID-19: A review of the current data
- Contraception, Hormone Replacement Therapy, and Cardiovascular Disease
- Supplement use in CV patients: What you need to know
- Heart Failure: Evidenced-based pharmacologic therapies
- Impacts of SGLT2s and GLP1s on CVD, Diabetes, and Renal Function
Member Cost: $35Non-member Cost: $75
Credits: 4.25 CE contact hours, 4.25 CE pharmacology hours
Learning Objectives
- Prevention and Treatment of COVID-19: A review of the current data
- Review current data on vaccines available for prevention of COVID-19, as well as contraindications and precautions.
- Discuss the current treatment guidelines for patients with COVID-19 in the outpatient and inpatient settings.
- Identify any new or emerging pharmacologic treatments for prevention and/or treatment of COVID-19.
- Contraception, Hormone Replacement Therapy, and Cardiovascular Disease
- Review current contraception choices their effectiveness and associated risks.
- Discuss drug drug interactions with contraceptive therapies and common cardiovascular medications.
- Outline patient centered approaches to counseling women with heart disease regarding contraception options
- Review current recommendations for menopausal hormone therapy and the relationship with CVD health outcomes and risks.
- Supplement Use in CV Patients: What you need to know
- Identify the most common supplements used for prevention and management of cardiovascular disease.
- Summarize current research conclusions regarding common supplements used for cardiovascular health.
- Review supplements with known harmful interactions with commonly used cardiovascular medications.
- Identify reliable resources for HCPs and patients on the use of nutritional supplements.
- Heart Failure: evidence-based pharmacologic therapies
- Review clinical practice guidelines for the treatment of heart failure.
- Discuss the drug classes used in evidenced based heart failure management.
- Describe how to select the right drug for the right patient, considering HF type and class, co-morbid conditions, and cost.
- Apply heart failure prescribing algorithms to clinical case studies.
- Impacts of SGLT2s and GLP1s on CVD, Diabetes, and Renal Function
- Review the studies showing the cardio-protective effects of SGLT2is and GLP1 RAs.
- Explain the role, function and side effects of SGLT2 inhibitors and GLP1 receptor agonists.
- Discuss the weight loss benefits of GLP1 RAs and SGLT2is.
- Summarize the renal benefits for patients with T2DM prescribed SGLT2is or GLP1 RAs.
Faculty
- Ty Gluckman, MD, FACC, FAHA
- Pamela Morris, MD, FACC, FAHA, FASPC, FNLA
- Rhonda Cooper-Dehoff, PharmD, MS, FAHA, FACC, FCCP
- Kimberly Cuomo, RN, MSN, CNRP, CHFN
- Eryn Bryant, MSN, NP-C
PCNA is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030602.